It is not clear whether combination therapy with immunomodulators affects the immunogenicity of tumor necrosis factor (TNF) antagonists in patients with inflammatory bowel disease.
T he drugs targeting tumor necrosis factor (TNF)-a that are currently used to treat inflammatory bowel disease (IBD) have been studied thoroughly for their efficacy and safety. Although a large percentage of patients (70%-90%) initially respond to the treatment, the remission rates after induction are still low (20%-50%) and patients are at risk to lose response over time. 1 The complex pharmacokinetics and considerable interindividual variability of clearance and immunogenicity have been implicated in the mechanism a Authors share co-first authorship.
of primary and secondary nonresponse. In particular, immunogenicity in the form of antidrug antibodies (ADAs) can impede the clinical response by affecting the bioavailability, pharmacokinetics, and pharmacodynamics of drugs. 2 Concomitant immunomodulators therapy has been shown to be clinically superior to monotherapy in clinical trials of Infliximab (IFX) and population cohorts of IFX-and adalimumab-treated patients. [3] [4] [5] Whether immunomodulators are protective against ADAs formation in patients treated with anti-TNFs remains unclear. There were studies investigating whether the concurrent immunomodulators with anti-TNF could lead to increased drug levels compared with anti-TNF monotherapy, but the results were inconsistent and conclusion remains unclarified. [6] [7] [8] Moreover, whether the effect of concomitant immunomodulators is similar in different kinds of anti-TNFs has seldom been evaluated. Herein, we aimed to determine the associations between concurrent immunomodulators with the ADAs formation and serum drug levels in different subgroups of antiTNFs by meta-analysis.
Methods
The study was performed following the Preferred Reporting Items for Systematic Reviews and Metaanalyses guidelines. 9 
Eligibility Criteria
We included all studies (controlled trials, observational studies, and cohort studies) that reported the frequency of ADAs formation, clinical outcomes, and/or serum anti-TNF-a levels in patients treated with anti-TNF-a agents. Inclusion criteria of the studies were as follows: (1) patients included adults or pediatrics with established IBD, (2) intervention included concomitant use of immunomodulators, (3) comparisons groups included those treated with anti-TNF-a agents (IFX, adalimumab, certolizumab, or golimumab) with or without immunomodulators, and (4) outcome included rate of patients who developed ADAs.
We excluded (1) trials in which the development of ADAs and/or the association between drug efficacy and serum levels were not systematically documented, (2) trials examining patients with reinitiating the same antiTNFs, (3) review articles, and (4) studies examining anti-TNF-a use in patients without IBD.
Literature Search
Studies investigating the association between clinical efficacy and infusion reactions with anti-TNF-a drug levels and the presence of ADAs were searched using PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials up to December 2015. The MeSH headings and keywords used were as follows: (antibody OR antibodies OR immunogenicity OR 'serum levels') AND (anti-TNF OR TNF-alpha OR TNF-a OR "human anti-chimeric antibodies (HACAs)," infliximab OR adalimumab OR certolizumab OR golimumab) AND ('Inflammatory bowel disease' and 'Crohn' OR 'ulcerative colitis') and any appropriate abbreviations. The final queries were validated by manual review and matching results.
The conference proceeding abstracts for American Digestive Diseases Week, European Crohn's and Colitis Organization, and the United European Gastroenterology Week between 2002 and 2015 were also searched. The reference lists of eligible studies and review articles were also checked manually to identify other relevant publications.
Study Selection
Two coauthors (Y.Q., R.M.) independently reviewed the retrieved articles according to a standardized data extraction form. All abstracts were screened to eliminate duplicates, reviews, case studies, and trials that did not have institutional review board approval. The primary authors of abstracts and studies without sufficient data were contacted for additional information. In duplicated reports, the most comprehensive article was chosen. Studies were excluded if the crude rates of ADAs or drug level could not be retrieved.
Data Extraction and Quality Assessment
Two investigators (Y.Q., R.M.) independently retrieved data on the patients' characteristics, therapeutic regimens, sample size, trial duration, and outcome measures. The quality of randomized controlled trials and observational studies were assessed using the Cochrane risk of bias tool 10 and Newcastle Ottawa Quality Assessment Scale, 11 respectively. For the Newcastle Ottawa Quality Assessment Scale, studies scores >7 (of 9) were graded as high quality.
Outcomes Assessed
The primary outcome was to compare the rate of ADAs formation in patients receiving anti-TNF combination therapy with immunomodulators versus anti-TNF monotherapy. The secondary outcome was to determine the influence of concomitant use of immunomodulators on trough level of anti-TNF.
Exploration of Heterogeneity
Sensitivity analysis. To assess the effect of each individual study on the summary estimates, an influence analysis was performed with the METAINF command in STATA. This sensitivity analysis was performed for the overall effect estimate for outcomes if there were >3 studies in a meta-analysis.
Subgroup and metaregression analysis. The extent of heterogeneity across studies was quantified by calculating the I 2 statistic. 12 Interaction test was performed to determine whether there are significant differences between the subgroups. If the calculated P value is significant (usually set at P < .05), there is a high probability of an association between the particular subgroup and outcome of interest. 13, 14 We preidentified several potential sources of heterogeneity: (1) patient enrollment (consecutive or unclear); (2) quality of study (high quality only); (3) time intervals between the assay and drug delivery; (4) 15 Metaregression analysis to investigate the sources of heterogeneity was only performed if there were >10 trials available for each analysis. This statistical approach determined whether there was a significant association between an independent variable (in the form of study or intervention characteristics like study time point, type or dose of immunomodulators) and the dependent variable of ADAs formation. 16 
Publication Bias
Funnel-plot asymmetry as proposed by Begg and Egger et al 17 was used to investigate the possibility of publication bias.
Data Synthesis and Statistical Analysis
We constructed 2 Â 2 tables (eg, the rate of ADAs formation for combination therapy with immunomodulators versus anti-TNFs monotherapy) from the raw extracted data. For estimate of standardized mean difference or weighted mean differences, we used 2 simple formulas proposed by Hozo et al 18 to estimate the mean using the values of the median, the low and high ends of the range, and the sample size.
Risk ratio (RR) and 95% confidence intervals (CI) were calculated using the Mantel-Haenszel methods and are displayed as the Z statistic and P value. Heterogeneity caused by study variation was assessed using the chisquare test, with P < .10 being considered as statistically significant. 19 The random-effects model was applied in case of statistically significant heterogeneity across the studies. 20 All analyses were performed using the Review Manager 5 software (RevMan 2011, The Cochrane Collaboration, Oxford, UK) and Stata version 12.1 (Stata Corp, College Station, TX) with the commands metan and metareg (for metaregression). All statistical tests were 2-sided, and statistical significance was defined as P < .05. Figure 1 included in the final analysis. Of these 35 studies, 11 studies 7, 24, 32, 34, [37] [38] [39] 43, 47, 48, 50 reported combined data from both CD and UC patients and were thus classified as "mixed IBD" for the meta-analysis. The main characteristics of the included studies are detailed in Table 1 . All included randomized controlled trials were rated as having low risk of bias except for 1 study. 29 Thirteen of the 23 observational studies were considered high quality (scoring >7) using the Newcastle Ottawa Quality Assessment Scale. Detailed quality assessments are provided in Supplementary Table 2 
Results

Study Characteristics
Subgroup Analysis of Crohn's Disease and Ulcerative Colitis
When subgroup analysis was conducted by type of disease (ie, CD, UC vs mixed IBD), the estimated RR of ADAs formation between patients on anti-TNF with or without concomitant use of immunomodulator did not differ significantly (P ¼ .34 for interaction test).
Specifically, 13 studies 3-5,8,9,21-27,37 of patients with CD were suitable for inclusion into a subgroup metaanalysis, with pooled data on 2382 patients. The prevalence of ADAs formation ranged from 0%-75.4% (mean, 17.5%). The RR of ADAs formation in patients with concomitant use of immunomodulators was 0.49 (95% CI, 0.38-0.62; P < .001) compared with that of patients receiving anti-TNFs monotherapy.
Only 4 studies 28, 30, 42, 43 reported raw data on the outcome of patients with UC alone. The prevalence of ADAs formation ranged from 0%-40.4% (mean, 7.3%). The pooled RR of ADAs formation in patients with UC treated with concomitant immunomodulators was 0.25 (95% CI, 0.08-0.79; P < .001).
Seven studies 29, 31, 34, 36, 40, 44, 45 reported results in a mixed population of patients with IBD. The prevalence of ADAs formation ranged from 22.4%-46%. The RR of ADAs formation for combination therapy was 0.56 (95% CI, 0.45-0.69; P < .001).
Subgroup Analysis of Different Anti-Tumor Necrosis Factor
We then subgrouped the studies by type of anti-TNFs. IFX, adalimumab, certozulimab, and golimumab were used in 19, 2, 2, and 1 studies, respectively. In the study by van Schaik et al, 48 patients were treated with either IFX or adalimumab and data were extracted separately. The pooled RR of ADAs formation in patients with combination therapy of IFX and immunomodulators was 0.51 (95% CI, 0.42-0.62; P < .001; n ¼ 2567) compared with patients with IFX monotherapy. The pooled RR of ADAs formation in patients with adalimumab combination therapy was 0.54 (95% CI, 0.25-1.17; P ¼ .06; n ¼ 416). The pooled RR of ADAs formation in patients with CZP combination therapy was 0.31 (95% CI, 0.14-0.70; P ¼ .003; n ¼ 544). For patients with golimumab treatment, the random-effects pooled incidence of ADAs formation was 0.29 (95% CI, 0.10-0.83; P ¼ .02; n ¼ 1103), which was also in favor of patients on concurrent immunomodulators. However, the estimated RR of ADAs formation in patients treated with different anti-TNFs did not differ significantly between patients treated with or without concomitant immunomodulators (P ¼ .50 for interaction test).
The RR of ADAs formation in patients with concomitant use of thiopurines or MTX was 0.33 (95% CI, 0.21-0.52; P < .001) and 0.13 (95% CI, 0.03-0.55; P ¼ .006) when compared with that of patients receiving anti-TNFs monotherapy, respectively. However, the interaction test (P ¼ .06; Table 2 ) and the metaregression revealed that type of immunomodulators had no significant difference on the pooled effect.
Subgroup analyses based on type of ADAs assay (radioimmunoassay [RIA] or enzyme-linked immunosorbent assay [ELISA] or homogenous mobility shift assay [HMSA]; P ¼ .94 for interaction test), study design (P ¼ .19 for interaction test), and rationale for testing ADA/trough levels (per protocol assessment vs driven by clinical scenario; P ¼ .13 for interaction test) and prior anti-TNF exposure (P ¼ .27 for interaction test) did not significantly change the effect estimates ( Table 2) .
Effects of Immunomodulators on Serum Drug Levels
The effect of concomitant immunomodulators on serum drug levels was reported in 5 studies 8, 28, 38, 41, 48 with results reported in 609 patients with IBD. Three studies 28, 41, 48 reported significantly higher serum trough drug levels in patients with concomitant use of immunomodulators. However, the pooled analysis failed to demonstrate a significant difference in serum drug levels between patients with combination therapy and monotherapy (standardized mean difference, 0.11; 95% CI, -0.19 to 0.41; P ¼ .47; Figure 3 ) (weighted mean difference, 0.71; 95% CI, -1.49 to 2.91; P ¼ .53; Supplementary Figure 2) .
Effects of Antidrug Antibodies on Serum Drug Level
Because low serum drug levels have been associated with ADAs formation, we also examined the serum antiTNFs levels by the presence of ADAs. Five studies 7, 28, 34, 41, 42 reported serum anti-TNFs levels according to ADAs status with a standardized mean difference of -0.57 (95% CI, -0.96 to -0.18; P ¼ .004; n ¼ 679; Supplementary Figure 3 ) favoring the group with undetectable ADAs.
Sensitivity Analysis
In metaregression analyses, the association between immunomodulators and ADAs was not substantially altered by the type of assays, anti-TNFs, diseases, or immunomodulators. In the present meta-analysis, most studies used ELISA to assess ADAs, as demonstrated in Table 1 , except for 4 studies that used HMSA, 34, 35, 37, 46 2 studies 30, 35 that used RIA, and 1 study that used a highperformance liquid chromatography-based fluid phase assay. 36 Most of the available literature described ADAs assessment using double antigen ELISA, except for 1 study that used bridging ELISA 48 and another study that used antihuman l chain. Excluding these 2 studies had little effect on the pooled effect estimate. In addition to concomitant immunomodulators use, several other factors including gender, disease burden, body mass index, and C-reactive protein may influence immunogenicity. However, metaregression analysis was not performed because of the lack of the required number of studies.
We also performed influence analysis to evaluate the weight of each individual study on the summary effect estimate by omitting 1 study at a time and recalculating the summary statistic for the RR of the remaining studies. There was no evidence of individual study dominance on the summary effect estimate (Supplementary Table 3) .
No statistical heterogeneity was found in the main subgroup analysis except for the comparison of the effect of immunomodulators on ADAs in patients with UC (I 2 ¼ 76%; P ¼ .002).
Publication Bias
Both Begg funnel plot ( Figure 4 ) and Egger test (P ¼ .001) showed a publication bias.
Discussion
Several observational studies and randomized controlled trials have examined the association between concurrent use of immunomodulators and ADAs formation in treatment of patients with IBD. To the best of our knowledge, the present study is the first meta-analysis to investigate the pooled impact of concomitant immunomodulators on immunogenicity of all approved antiTNFs including IFX, adalimumab, certolizumab, and golimumab in patients with IBD. Overall, patients with IBD who are on anti-TNF-a with the concomitant use of immunomodulators had a 51% reduced risk of developing ADAs compared with patients on anti-TNF-a monotherapy.
The influence of combination therapy with immunomodulators on the drug level and antibodies in patients treated with adalimumab, CZP, and golimumab has been poorly investigated. Baert et al 51 recently showed that the concomitant use of immunomodulators with adalimumab therapy initiation prevented ADAs formation. However, Paul et al 52 and Mazor et al 44 found that concomitant use of immunomodulators did not influence drug levels of adalimumab. In a retrospective study of 217 patients treated with adalimumab, van Schaik et al 48 found no beneficial effect of immunomodulators combination for preventing ADAs formation. In the present study, patients treated with adalimumab and immunomodulators had a lower ADA rate with a pooled RR of 0.54, but this was not statistically significant (P ¼ .06). In contrast, the pooled RR of ADAs formation in patients treated with CZP who were on concurrent immunomodulators was 0.31 (P ¼ .003). In patients treated with golimumab, the random-effects pooled incidence of ADAs was 0.29 (P ¼ .02), which was also in favor of patients on concurrent use of immunomodulators. However, the estimated RR of ADAs formation in patients treated with different anti-TNFs did not differ significantly between patients treated with or without concomitant immunomodulators by subgroup analysis.
Factors that would influence the formation of ADAs include dose, dosing intervals, scheduled/episodic therapy, concomitant use of immunomodulators, degree of product humanization, and so forth. [21] [22] [23] 28 Although patients treated with thiopurines had higher incidence of ADAs formation compared with patients treated with MTX (0.33 vs 0.13) in our meta-analysis, both the interaction test and the metaregression revealed that type of immunomodulators had no significant difference on the pooled effect. Identifying which kind of immunomodulators (azathioprine, mercaptopurine, or MTX) provides greater protection against immunogenicity remains to be determined. It is reported that patients previously treated with IFX with high levels of antibodies to IFX have a lower response rate to adalimumab than patients with low levels of antibodies to IFX. 30 This indicated that prior anti-TNFs exposure might influence ADAs formation. However, our study showed that patients with prior anti-TNFs exposure had a similar rate of ADAs formation compared with patients naive to anti-TNFs. Moreover, other factors including type of ADAs assay (RIA or ELISA or HMSA) and rationale for testing ADA had no influence on the rate of ADAs formation.
It has been reported that concurrent immunomodulators use was associated with a 14% decrease in IFX clearance in children and adults. 53 This resulted in decreased drug levels in the circulation and the concomitant restoration of effective anti-TNFs levels. Detectable serum anti-TNFs concentrations have consistently been associated with clinical remission and endoscopic improvements, and an undetectable trough serum IFX level predicts an increased risk for colectomy. 6 Some studies reported that serum trough drug levels were significantly higher in patients treated with concomitant use of immunomodulators. 28, 41, 48 However, the pooled analysis in our meta-analysis failed to demonstrate a significant difference in serum drug levels between patients in combination therapy and monotherapy.
This meta-analysis is potentially limited in some ways. First, an assessment of the methodological quality determined that there were deficiencies in studies evaluated, because 10 of the 23 observational studies were considered low-quality. Second, different types of ADAs assay (RIA or ELISA or HMSA) were used in the included studies, which may result in the heterogeneity across studies. Our subgroup analyses demonstrated that type of ADAs assay did not significantly change the effect estimates. This was supported by a recent study that revealed a good correlation among 3 different assays for measuring drug level and antibody of IFX. 54 Finally, because of lack of sufficient data reported in the original publications, it was not possible to evaluate the effect of other factors, such as gender, disease burden, body mass index, and C-reactive protein, on the rate of ADAs formation.
In conclusion, the current evidence suggested that concurrent use of immunomodulators was associated with lower risk of ADAs formation in patients with IBD receiving anti-TNF treatment. Concomitant use of immunomodulators should be considered in patients treated with anti-TNF treatment. 
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